Evidence mapPaperPMID 30961501Full record

ReviewCurrent vascular pharmacology2020

The Growing Epidemic of Diabetes Mellitus.

Dragan Lovic, Alexia Piperidou, Ioanna Zografou, Haralambos Grassos, Andreas Pittaras, Athanasios Manolis

Registry-linked trialAbstract readReview
PubMed Publisher
In one paragraph

Review in Current vascular pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06759922 (Clinical Efficacy and Safety of Glimepiride, Empagliflozin and Sitagliptin With Metformin in Type 2 Diabetes Mellitus), which is not on this map. Cited by 255 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
255citing papers in PubMed, 9 pooled it
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06759922 phase4completedstarted 2025, after this paper: background citation

Clinical Efficacy and Safety of Glimepiride, Empagliflozin and Sitagliptin With Metformin in Type 2 Diabetes Mellitus: A Double and Triple Drug Therapy

Ran2025Enrolled172Registered outcomes2Posted comparisons0ConditionsType 2 Diabetes MellitusArmsTab Metformin + Tab Empagliflozin, Tab Metformin + Tab Empagliflozin + Tab Sitagliptin, Tab Metformin + Tab Glimepiride, Tab Metformin +Tab Sitagliptin
Open the trial in the graph
3 · Its place in the literature

Who cites it

255 citing papers in PubMed, 9 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Frontiers in pharmacology · 2024
    Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Trial
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

195 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Dragan LovicClinic for Internal Disease Intermedica, Nis, Serbia.
Alexia Piperidou2nd Propedeutic Department of Internal Medicine, Aristotle University, Thessaloniki, Greece.
Ioanna Zografou2nd Propedeutic Department of Internal Medicine, Aristotle University, Thessaloniki, Greece.
Haralambos GrassosCardiology Department, KAT Hospital, Athens, Greece.
Andreas PittarasCardiology Department, Asklepeion Hospital, Athens, Greece.
Athanasios ManolisCardiology Department, Asklepeion Hospital, Athens, Greece.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDuring the past decades, the prevalence of diabetes (DM) has increased significantly, mainly as a result of continuous rise in the incidence of type 2 DM. According to World Health Organization statistics, >422 million adults globally were suffering from DM in 2014 and a continuous rise in DM prevalence is expected.

objectiveThe present review considers recent epidemiological data providing worldwide estimates regarding the incidence of DM.

methodsA comprehensive literature search was conducted to identify available data from epidemiological studies evaluating the current burden of DM.

resultsOver the past few decades the prevalence of DM has risen significantly in nearly all countries and may be considered as a growing epidemic. Urbanization and income status are major factors which influence current rates in the prevalence studies introducing interesting differences between several population groups.

conclusionHaving recognized the global burden of DM, we now realize the urgent need for effective interventions. In order to monitor the public-health strategies and design effective future interventions we need reliable global estimates regarding the prevalence of DM.

Indexed as

EpidemicsAdultAgedDiabetes MellitusFemaleHumansIncidenceMaleMiddle AgedPrevalencePrognosisRisk AssessmentRisk FactorsTime FactorsDiabetes mellitusepidemiologygestational diabetesimpaired fasting glycaemiaimpaired glucose toleranceincidenceprevalencetype 1 diabetestype 2 diabetes.

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.